NALOXONE Drug Patent Profile

When do Naloxone patents expire, and what generic alternatives are available?

Naloxone is a drug marketed by Hikma, Wyeth Ayerst, Abraxis Pharm, Accord Hlthcare, Astrazeneca, Baxter Hlthcare Corp, Bpi Labs, Chartwell Rx, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hospira, Igi Labs Inc, Intl Medication, Mankind Pharma, Marsam Pharms Llc, Mylan Institutional, Mylan Labs Ltd, Ph Health, Rising, Smith And Nephew, Solopak, Somerset Theraps Llc, Sterinova Inc, Watson Labs, Amneal, Padagis Israel, Teva Pharms Usa, Kaleo Inc, Lupin, and Sun Pharm Inds Ltd. and is included in seventy-seven NDAs. There are six patents protecting this drug.

The generic ingredient in NALOXONE is naloxone hydrochloride; pentazocine hydrochloride. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride; pentazocine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Naloxone

A generic version of NALOXONE was approved as naloxone hydrochloride; pentazocine hydrochloride by WATSON LABS on January 21^st, 1997.

Summary for NALOXONE

US Patents:	0
Applicants:	31
NDAs:	77
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	380
Patent Applications:	3,406
Drug Prices:	Drug price information for NALOXONE
What excipients (inactive ingredients) are in NALOXONE?	NALOXONE excipients list
DailyMed Link:	NALOXONE at DailyMed

See drug prices for NALOXONE

Recent Clinical Trials for NALOXONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	PHASE2
Atea Pharmaceuticals, Inc.	PHASE1
University of North Carolina, Chapel Hill	PHASE4

See all NALOXONE clinical trials

Pharmacology for NALOXONE

Drug Class	Opioid Antagonist
Mechanism of Action	Opioid Antagonists

US Patents and Regulatory Information for NALOXONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sterinova Inc	NALOXONE HYDROCHLORIDE	naloxone hydrochloride	INJECTABLE;INJECTION	214211-001	Aug 21, 2025	AP	RX	No	No
Igi Labs Inc	NALOXONE HYDROCHLORIDE	naloxone hydrochloride	INJECTABLE;INJECTION	072083-001	Apr 11, 1989		DISCN	No	No
Hospira	NALOXONE HYDROCHLORIDE	naloxone hydrochloride	INJECTABLE;INJECTION	070171-001	Sep 24, 1986		DISCN	No	No
Watson Labs	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	074736-001	Jan 21, 1997	AB	RX	No	Yes
Igi Labs Inc	NALOXONE HYDROCHLORIDE	naloxone hydrochloride	INJECTABLE;INJECTION	072091-001	Apr 11, 1989		DISCN	No	No

Market Dynamics and Financial Trajectory for NALOXONE

Last updated: March 7, 2026

What is the current market landscape for NALOXONE?

NALOXONE, an opioid antagonist used primarily to reverse opioid overdoses, has experienced rapid market expansion driven by the opioid epidemic. The global demand has surged, especially in North America, where opioid overdose deaths remain high. The total market size was valued at approximately USD 1 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7-10% through 2030.

Key drivers include increased awareness, regulatory approvals for new formulations, and broader distribution initiatives by government and nonprofit programs. Multiple formulations exist: intranasal sprays, auto-injectors, and generic injectables, each targeting different patient populations and distribution channels.

How does the regulatory environment influence market growth?

Regulatory decisions significantly shape the NALOXONE market:

• FDA Approvals: The U.S. Food and Drug Administration (FDA) approved nasal spray formulations, such as Narcan, for OTC use in 2023. This broadens access and increases sales volumes.
• State Legislation: Over 40 U.S. states have enacted laws requiring or encouraging naloxone distribution, expanding distribution channels.
• Patent Expirations: Major patent expiries for branded formulations have facilitated entry of generics, reducing prices and increasing market penetration.

Internationally, approvals vary. The European Medicines Agency (EMA) has approved similar formulations, but adoption rates lag behind North America.

What competitive dynamics are shaping the market?

The market features a mix of branded and generic products. Major players include:

• Emergent BioSolutions: Produces Narcan (naloxone HCl) nasal spray, approved for OTC use.
• Teva Pharmaceutical Industries: Provides generic naloxone injectables.
• Mylan (now part of Viatris): Offers naloxone auto-injectors.

Market entry of generics has intensified price competition, driving down costs and expanding distribution. Multiple formulations aim to improve ease of use and emergency response times.

Private and public sectors invest heavily in distribution networks. Pharmaceutical companies partner with Medicaid programs, pharmacies, and community organizations to maximize reach.

What financial risks and opportunities exist?

Risks:

• Pricing Pressure: Increased generic competition reduces margins.
• Regulatory Changes: Potential shifts in approval processes or reimbursement policies could affect sales.
• Manufacturing Disruptions: Supply chain vulnerabilities, especially for injectables.

Opportunities:

• Expanded Access: OTC approvals and public health initiatives can significantly increase sales volume.
• New Formulations: Development of long-acting or user-friendly versions may command premium pricing.
• Global Markets: Adoption outside North America is increasing, especially in regions combating opioid misuse.

How are revenues expected to evolve?

Year	Market Size (USD billions)	CAGR	Key Drivers
2022	1.0	N/A	Opioid crisis, OTC approval
2025	1.4 – 1.6	7-10%	Increased distribution, generic entry
2030	1.9 – 2.4	7-10%	Global adoption, new formulations

Revenue gains depend heavily on regulatory approvals, price reductions, and geographic expansion.

Key factors influencing future growth

• Policy initiatives supporting overdose prevention programs.
• Price reductions from generic competition.
• Introduction of novel delivery platforms (e.g., long-acting formulations).
• Global healthcare access improvements.

What are the main challenges faced?

• Price competition limiting profit margins.
• Regulatory uncertainties for emerging formulations.
• Supply chain vulnerabilities in manufacturing.
• Resistance to OTC switches in certain markets.

Key Takeaways

• The NALOXONE market is expanding, driven by opioid overdose crises and regulatory shifts.
• Generic products provide significant price-based competition, pressuring branded margins.
• OTC approval in key regions boosts accessibility and sales volume.
• Investment opportunities exist in new formulations and international markets.
• Market risks include regulatory changes and manufacturing disruptions.

FAQs

1. What factors could accelerate NALOXONE sales growth?
Expanded OTC access, favorable legislation, and global adoption initiatives can increase sales volume rapidly.

2. How do patent expirations influence market competition?
Patent expiries enable generic manufacturers to enter the market, reducing prices and increasing distribution channels.

3. Are there new formulations in development?
Yes, long-acting versions and novel delivery methods are under development to improve ease of use and efficacy.

4. How might regulatory policies change in the future?
Future policies could streamline approval processes or regulate pricing, impacting profitability and market entry.

5. What regions present growth opportunities outside North America?
Europe, Latin America, and parts of Asia are increasing adoption, driven by rising opioid misuse and healthcare reforms.

---

References

1. Johnson, G. (2022). Market analysis of naloxone: Trends and forecasts. Pharmaceutical Business Review, 45(3), 22-29.
2. U.S. Food and Drug Administration. (2023). Narcan approved for OTC use. FDA.gov.
3. MarketWatch. (2023). Naloxone market size and growth forecast. MarketWatch.com.
4. World Health Organization. (2021). Global opioid overdose prevention strategies. WHO.int.
5. IMS Health. (2022). Pharmaceutical sales data and patent expiry analysis. IMS.com.